Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal irinotecan plus mFOLFOX4 and bevacizumab for unresectable colorectal peritoneal metastases
NL-OMON56200Phase 2Recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in colorectal cancer (CRC), peritoneal carcinomatosis (PC) and colorectal peritoneal carcinomatosis (CRC-PC), sponsored by Catharina Ziekenhuis. Primary endpoints: Progression-free survival, Overall survival from diagnosis of peritoneal metastases and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)peritoneal carcinomatosis (PC)colorectal peritoneal carcinomatosis (CRC-PC)
Beyond the preview
Go deeper on NL-OMON56200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56200.